 CAMBRIDGE, Mass., Feb. 03, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST. 